Santen Pharmaceutical CoSNPHF +4.40%81 Buyback Yield % is 4.78 as of Jul. 04, 2026, which is 3% below its 10-year median of 4.92. GuruFocus rates SNPHF with a GF Score™ of 81/100 and a GF Value™ of $10.25 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 292 Drug Manufacturers companies, Santen Pharmaceutical Co ranks better than 96.23% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNPHF vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co (SNPHF) has a Buyback Yield % of 4.78 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Santen Pharmaceutical Co and its competitors. This is near median its historical median of 4.92. Over the past decade, Santen Pharmaceutical Co's Buyback Yield % has ranged from 1.72 to 7.83. According to the industry distribution chart, Santen Pharmaceutical Co ranks #11 out of 292 companies in the Drug Manufacturers industry, placing it in the top 3.8%.
Is Santen Pharmaceutical Co's Buyback Yield % too high?
Santen Pharmaceutical Co's current Buyback Yield % of 4.78 is near median its 10-year median of 4.92. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 7.83. Based on the distribution chart, Santen Pharmaceutical Co ranks #11 out of 292 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Santen Pharmaceutical Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #11 out of 292 companies for Buyback Yield %. This places Santen Pharmaceutical Co in the top 4% of its industry — outperforming the majority of peers. Historically, Santen Pharmaceutical Co's own Buyback Yield % has ranged from 1.72 to 7.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Buyback Yield % is 4.78, which is near median its own 10-year median of 4.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.25, compared to a current price of $13.05 — trading 27.3% above its estimated fair value. The current Buyback Yield % is 4.78, which is near median its 10-year median of 4.92. Santen Pharmaceutical Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Buyback Yield % is 4.78 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $13.05 is trading 27.3% above its estimated GF Value™ of $10.25.
GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SNPHF:
Buyback Yield %: 4.78 (near median its 10-year median of 4.92)
GF Value™: $10.25 vs. price of $13.05 (27.3% above fair value)
No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
81GF Score
Get the complete analysis for SNPHF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHF has been successfully added to your 
